Bacterial pneumonia in HIV-infected patients: a prospective study of 68 episodes


ABSTRACT: We collected clinical and microbiological observations, as well as follow-up on human immunodeficiency virus (HIV)-infected patients with bacterial pneumonia, and compared pneumococcal pneumonia in patients with and without HIV infection.

Fifty five HIV-infected patients, who had had 68 episodes of bacterial pneumonia, were studied prospectively. Twenty one HIV-infected patients with pneumococcal pneumonia were compared to 69 non-HIV-infected patients with pneumococcal pneumonia.

Aetiological diagnosis was established in 48 cases (71%). The most common causative agents were S. pneumoniae and H. influenzae. Sixty percent of episodes took place in asymptomatic carriers of HIV infection and 37% in acquired immune deficiency syndrome (AIDS) patients. Overall mortality was 10%. Fifty five percent of patients with follow-up had recurrent episodes. Bacteraemic pneumococcal pneumonia was more frequent in HIV- than in non-HIV-infected patients, and the mortality of pneumococcal pneumonia was also higher in HIV- (19%) than in non-HIV-infected (4.3%) patients.

We conclude that bacterial pneumonia is a frequent problem in HIV-infected patients and that recurrent episodes are common. The clinical presentation of pneumococcal pneumonia is generally indistinguishable from that occurring in normal hosts, but bacteraemia is more common and the mortality is higher in HIV-infected patients.

Eur Respir J., 1994, 7, 235–239.

In the early years of the acquired immune deficiency syndrome (AIDS) epidemic, it was thought that opportunistic infections and neoplasms related to AIDS were directly caused by a progressive alteration of cell-mediated immunity, and that humoral immunity was not only intact but also overreactive, based on findings of elevated immunoglobulin levels, elevated levels of antibody to specific viral agents and normal to elevated numbers of B-cells [1, 2]. However, increased rates of bacterial pneumonias in human immunodeficiency virus (HIV) infected patients were reported in the following years [3–6]. The attack rate for pneumococcal pneumonia in HIV-infected patients is 18–45 per 1,000, which is significantly higher than the yearly estimated incidence rate for pneumococcal pneumonia in the general population, which is 3 per 1,000 [4, 7]. SELWYN et al. [8], in a prospective study of 159 intravenous drug users, found that 9% of seropositive patients had a bacterial pneumonia, while the incidence was only 2% in seronegative patients. YAMAGUCHI et al. [9] observed that the incidence of pneumococcal pneumonia in patients with HIV infection increased from 2% in 1985 to 9% in 1989.

Because bacterial pneumonia is the most prominent complication associated to B-cell dysfunction, it was thought that HIV-infected patients had B-cell abnormalities associated with the profound T-cell deficiency caused by HIV. Different authors have demonstrated marked abnormalities of B-cell activation and immunoregulation, directly at the level of the B-cell, as well as at the level of T-cell control of B-cell function [10–12].

In our hospital, we have also noticed an increasing incidence of bacterial pneumonia in HIV-infected patient; this led us to conduct a prospective study of all patients with HIV infection and community-acquired bacterial pneumonia, in order to record clinical and microbiological observations as well as follow-up data in these patients, and also to compare the clinical features of pneumococcal pneumonia in patients with and without HIV infection.

Material and methods

From February 1988 to October 1990, all patients with HIV infection who had a community-acquired bacterial
pneumonia were prospectively studied. Bacterial pneumonia was defined as an acute lower respiratory tract disease with fever (>38°C), and pulmonary infiltrates in X-ray chest film not seen on prior radiographs and/or resolving after antibiotic therapy. Patients in whom chest roentgenogram abnormalities were attributed to conges-
tive heart failure, pulmonary embolus or chronic under-
lying lung disease were excluded. Patients with right-sided endocarditis, metastatic pulmonary infection, pulmonary tuberculosis, Pneumocystis carinii pneumonia and ob-
structive pneumonitis due to lung cancer were also ex-
cluded.

For each patient, we recorded clinical and routine labo-
ratory data and chest roentgenogram observations. On
admission, all patients were instructed to deliver a spu-
tum sample as soon as possible. Blood cultures were
put in each patient before therapy was started. All spu-
tum samples were cultured for Legionella sp. Spu-
tum specimens were cultured for bacteria only if >25
polymorphonuclear leucocytes and <10 squamous epitel-
ial cells were present per low-power field on Gram-stain
[13]. After homogenization, quantitative sputum cul-
ture with a gauged handle was performed in all cases.
All patients were treated with a third generation cepha-
losporin.

A micro-organism was considered to be the causative
agent of pneumonia when at least one of the follow-
ing criteria was present: 1) visualization of the micro-
organism by Gram-stain of sputum and isolation of more
than 5×10⁶ (colony forming unit) cfu·ml⁻¹ in quantitative
sputum culture; 2) isolation of the micro-organism in
blood cultures and/or pleural fluid.

Respiratory failure was considered when blood gas
level showed severe hypoxaemia (arterial oxygen ten-
sion (Pao₂) <60 mmHg (8 kPa)) without oxygen admin-
istration. Shock was defined by clinical signs (systolic
arterial pressure <80 mmHg, tachycardia, urine output
<20 ml·h⁻¹, and clinical signs of reduction of tissue per-
fusion).

HIV antibodies were determined by enzyme immuno-
assay and confirmed by western-blot. Patients with HIV
infection were classified according to Center of Disease
Control (CDC) criteria (1987): Group I (primary infec-
tion); Group II (asymptomatic carrier); Group III (per-
sistent generalized lymphadenopathy); and Group IV
(AIDS).

Clinical and evolutive data of patients with HIV infec-
tion and pneumococcal pneumonia were compared to
those of 69 non-HIV-infected patients with pneumococ-
cal pneumonia. This control group of HIV negative
patients was obtained from a prospective study of all
community-acquired pneumonia carried out in our hos-
ital at the same time. There were 51 males and 18
women, with a mean age of 58 yrs.

A statistical analysis was performed using the Chi-
squared test, or Fisher’s exact test when expected values
were <5, to compare categorical variables. A multi-
variate analysis was performed using a regression model
to compare pneumococcal pneumonias in patients with
and without HIV infection and to obtain independent
variables to predict mortality.

Results

During the period of the study, 68 episodes of com-
munity-acquired pneumonia were diagnosed in 55 patients
with HIV infection. There were 39 males and 16 females,
with a mean age of 31 yrs (range 20–61 yrs). Forty six
 patients were intravenous drug users, four had haemophi-
ia, three were heterosexual partners of HIV-infected
patients, one was homosexual, and the remaining acquir-
ed the infection after blood transfusion.

Forty one episodes (60%) took place in asymptomatic
 carriers of HIV (Group II), two in patients with persistent
generalized lymphadenopathy (Group III) and 25
 patients already had an AIDS diagnosis (Group IV). The
opportunistic diseases in patients with an AIDS diag-
nosis before the bacterial pneumonia are listed in table
1. Thirty seven patients were under oral zidovudine
therapy and 32 were receiving prophylaxis for Pneumo-
cystis carinii pneumonia (27 with sulphamethoxazole-
trimethoprim and 5 with inhaled pentamidine). The length
of time from the diagnosis of HIV infection to the de-
velopment of bacterial pneumonia varied from 1–60 months
(mean 18 months). Fifteen of the 55 patients had no
previous diagnosis of HIV infection when they had the
bacterial pneumonia.

In table 2 clinical, laboratory and radiological findings
in HIV-infected patients with bacterial pneumonia are
summarized. Nearly all patients presented with fever

Table 1. – Opportunistic diseases in 25 AIDS patients
with bacterial pneumonia

<table>
<thead>
<tr>
<th>Disease</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumocystis carinii pneumonia</td>
<td>12</td>
</tr>
<tr>
<td>Extrapulmonary tuberculosis</td>
<td>8</td>
</tr>
<tr>
<td>Recurrent Salmonella enteritidis bacteraemia</td>
<td>5</td>
</tr>
<tr>
<td>Brain toxoplasmosis</td>
<td>3</td>
</tr>
<tr>
<td>Disseminated cryptococcosis</td>
<td>3</td>
</tr>
<tr>
<td>Oesophageal candidiasis</td>
<td>1</td>
</tr>
<tr>
<td>Progressive multifocal leucoencephalopathy</td>
<td>1</td>
</tr>
<tr>
<td>Disseminated cytomegalovirus disease</td>
<td>1</td>
</tr>
<tr>
<td>Cryptosporidiosis</td>
<td>1</td>
</tr>
</tbody>
</table>

AIDS: acquired immune deficiency syndrome.

Table 2. – Clinical presentation, laboratory and radi-
ological findings in 68 episodes of 55 HIV-infected patients
with bacterial pneumonia

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Episodes</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>68</td>
<td>100</td>
</tr>
<tr>
<td>Productive cough</td>
<td>59</td>
<td>87</td>
</tr>
<tr>
<td>Chest pain</td>
<td>50</td>
<td>74</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>15</td>
<td>22</td>
</tr>
<tr>
<td>Shock</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>White cell count &lt;4×10⁶·l⁻¹</td>
<td>21</td>
<td>31</td>
</tr>
<tr>
<td>White cell count &gt;10×10⁶·l⁻¹</td>
<td>23</td>
<td>34</td>
</tr>
<tr>
<td>Unilateral infiltrate</td>
<td>60</td>
<td>88</td>
</tr>
<tr>
<td>Bilateral infiltrates</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>Cavitation</td>
<td>4</td>
<td>6</td>
</tr>
</tbody>
</table>

HIV: human immunodeficiency virus.
productive cough (87%) and chest pain (74%). Severe complications, such as respiratory failure, were present in 15 patients (22%). Intubation and mechanical ventilation were necessary in two cases. Although all patients had radiological signs of consolidation, only 62% had physical signs of pneumonia, eight patients had bilateral infiltrates, and eight had pleural effusion. When cavitation was present on the X-ray film (table 2) the aetiological agents were *Streptococcus pneumoniae*, *Bacillus sphericus*, *Acinetobacter calcoaceticus* and *Streptococcus sp.*

An aetiological diagnosis of bacterial pneumonia was established in 48 cases. The most common causative agents were *S. pneumoniae*, which caused 23 episodes (34%), and *H. influenzae*, which was responsible for 12 cases (18%). Other organisms isolated were *P. aeruginosa* in four patients, and other Gram-negative bacilli in four cases. The remaining microorganisms were responsible for only one case each (table 3). Bacteremia was detected in 19 cases.

We have compared 21 pneumococcal pneumonias in HIV-infected patients with 69 pneumococcal pneumonia in non-HIV infected patients (table 4). In the univariate analysis, non-HIV-infected patients were more likely to have chronic obstructive lung disease as underlying condition (p<0.01), purulent sputum (p<0.01) and signs of chest consolidation (p<0.01). Patients with HIV infection and pneumococcal pneumonia more frequently had chronic liver disease (p<0.05), bacteremia (p<0.05) and a higher mortality (p<0.05).

In the multivariate analysis, only physical signs of chest consolidation were more frequent in non-HIV-infected patients (p<0.01; odds ratio=12), and bacteremia was more frequently detected in HIV-infected patients (p<0.01; odds ratio=4).

Thirteen patients (19%) had a total lymphocyte count below 0.5×10^9·l^{-1}, 28 (41%) between 0.5 and 1×10^9·l^{-1}, and 27 (40%) more than 1×10^9·l^{-1}. Twenty four out of 31 patients (77%) had a total CD4 count below 0.2×10^9·l^{-1}.

Seven patients died, giving an overall mortality of 10%. When we compared patients who died with those who survived, we found the following factors to be associated with a higher mortality: development of respiratory failure (p<0.05), shock (p<0.05), more than one lobe involved in X-ray chest film (p<0.05), presence of pleural effusion (p<0.05) and an absolute lymphocyte count below 1×10^9·l^{-1}. However, the multivariate analysis showed that the only independent variables to predict mortality were pleural effusion (p<0.01; odds ratio=46) and an absolute lymphocyte count below 1×10^9·l^{-1} (p<0.01; odds ratio 4).

Thirty one patients were followed up for 1–31 months after they had recovered from pneumonia. Seventeen of them had another bacterial pneumonia after recovering from the previous episode. Twelve of these patients were receiving co-trimoxazole for primary or secondary prevention of *P. carinii* pneumonia. The recurrent episodes developed in the first 2 months in 10 patients. Seven out of 16 patients that were asymptomatic carriers of HIV developed an AIDS defining condition in a mean time of 10 months.

### Table 3. – Aetiology of community-acquired bacterial pneumonia (68 episodes) in 55 HIV-infected patients

<table>
<thead>
<tr>
<th>Aetiological Agent</th>
<th>Episodes</th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>22</td>
<td>(34%)</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td>12</td>
<td>(18%)</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Other Gram-negative bacilli</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><em>Bacillus sphericus</em></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><em>Mycoplasma pneumoniae</em></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><em>Moraxella catarrhalis</em></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><em>Streptococcus spp.</em></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>48</strong></td>
<td>(71%)</td>
</tr>
<tr>
<td><strong>Unknown</strong></td>
<td><strong>20</strong></td>
<td>(29%)</td>
</tr>
</tbody>
</table>

HIV: human immunodeficiency virus.

### Table 4. – Comparison between HIV-infected patients with pneumococcal pneumonia (Group 1) and non-HIV-infected patients with pneumococcal pneumonia (Group 2)

<table>
<thead>
<tr>
<th></th>
<th>Group 1 HIV-infected</th>
<th></th>
<th>Group 2 non-HIV-infected</th>
<th></th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients</td>
<td>21</td>
<td></td>
<td>69</td>
<td></td>
<td>p&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Smokers</td>
<td>18</td>
<td>86</td>
<td>36</td>
<td>52</td>
<td>p&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Chronic obstructive lung disease</td>
<td>0</td>
<td></td>
<td>26</td>
<td>38</td>
<td>p&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>6</td>
<td>29</td>
<td>5</td>
<td>7</td>
<td>p&lt;0.05</td>
<td></td>
</tr>
<tr>
<td>Productive cough</td>
<td>20</td>
<td>95</td>
<td>64</td>
<td>93</td>
<td>p&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Purulent sputum</td>
<td>8</td>
<td>38</td>
<td>52</td>
<td>75</td>
<td>p&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Chest pain</td>
<td>13</td>
<td>62</td>
<td>40</td>
<td>58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest consolidation</td>
<td>14</td>
<td>67</td>
<td>66</td>
<td>96</td>
<td>p&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>6</td>
<td>29</td>
<td>17</td>
<td>25</td>
<td>p&lt;0.05</td>
<td></td>
</tr>
<tr>
<td>Shock</td>
<td>3</td>
<td>14</td>
<td>8</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacteraemia</td>
<td>15</td>
<td>71</td>
<td>28</td>
<td>41</td>
<td>p&lt;0.05</td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td>4</td>
<td>19</td>
<td>3</td>
<td>4</td>
<td>p&lt;0.05</td>
<td></td>
</tr>
</tbody>
</table>

OR: odds ratio; HIV: human immunodeficiency virus.
Discussion

The incidence of bacterial pneumonia is increased in HIV-infected patients [4, 7, 8, 14–16]. In our study, we describe 68 episodes of bacterial pneumonia, which actually constitutes one of the largest series.

An aetiological diagnosis was obtained in nearly 71% of cases. A majority of community-acquired bacterial pneumonias seen in AIDS patients are caused by Strep-
tococcus pneumoniae and Haemophilus influenzae [4, 7, 8, 17]. Both micro-organisms were the causative agents in more than 50% of our patients. Other organisms such as Legionella pneumophila, which is the second agent of community-acquired pneumonia in our hospital [18], is very unusual [19]. Although Staphylococcus aureus was responsible for 6% of respiratory complications in HIV-infected patients in one study [20], it has been the cause of only one case in our series.

Four patients had a pneumonia caused by Pseudomonas aeruginosa. All of these patients had an advanced stage of HIV infection with a very low lymphocyte count, although they also had granulocytopenia as a predisposing factor to P. aeruginosa infection. However, of nine AIDS patients with community-acquired pneumonia caused by P. aeruginosa in the study reported by FRANZETTI et al. [21], none had granulocytopenia, suggesting that the occurrence of Pseudomonas aeruginosa pneumonia should certainly be regarded as an indicator of progression of immunodeficiency. Recently, FRIED and ROMANO [22] have also reported four cases of pneumonia caused by P. aeruginosa in AIDS patients; therefore, it should be considered that P. aeruginosa is not a rare cause of pneumonia in HIV-infected patients, especially in those with an advanced stage of immunosuppression. Mycoplasma pneumoniae is unusual in these patients [23].

An important point to consider is that 15 of the 55 patients (27%) had no diagnosis of HIV infection, so that bacterial pneumonia was the first manifestation of HIV infection. Some authors, therefore, stress the need to investigate the possibility of HIV infection in any young adult without an underlying disease and presenting with S. pneumoniae or H. influenzae pneumonia [24–27].

In general, the clinical presentation of bacterial pneumonia in HIV-infected patients is similar to that occurring in non-HIV-infected patients. Most patients have an acute onset of symptoms, and signs of fever, productive cough and chest pain are present in nearly all cases [28]. Although we found some differences in the clinical presentation of pneumococcal pneumonia between HIV-infected and non-infected patients, we think that, in general, they are not relevant. Atypical presentations or manifestations of pneumococcal disease are not frequent in HIV-infected patients, and the serotypes causing pneumococcal infection are the same in HIV- and non-HIV-infected patients [29]. It is important to note that bacteraemia is significantly more frequent in HIV-infected patients with pneumococcal pneumonia and the mortality is also higher. The higher rate of bacteraemia, which has been documented in other studies [30–33], is probably related to impairment of humoral immunity.

Forty three (63%) episodes of bacterial pneumonia took place in patients who had no previous opportunistic disease. SELWYN et al. [8] also reported that about 66% of their HIV-infected patients with bacterial pneumonia had no signs of an advanced stage of HIV infection. Bacterial pneumonia seems to be an early manifestation in the natural history of HIV infection, but we have to consider that 77% of patients had a total CD4 lymphocyte count below 200 cells·mm\(^{-3}\). In nearly half of the patients (7 of 16) who were asymptomatic carriers of HIV (Group II), an AIDS defining disease developed within a mean period of 10 months. HIV-infected patients with bacterial pneumonia may thus already have an important impairment of their immunological mechanisms, hence bacterial pneumonia could be a marker of progression to AIDS. PARRIN et al. [34] similarly observed that patients with bacterial infections, especially pneumonias, had a higher incidence of cytomegalovirus disease and Pneumocystis carinii pneumonia.

Despite the high incidence of bacteraemia and the impairment of their immunological system, the majority of patients responded to antimicrobial therapy; the mortality rate was 10%. Although mortality for pneumococcal pneumonia seemed higher in HIV-infected patients than in non-HIV-infected patients, multivariate analysis did not confirm this observation. In a recent study, AIDS patients with bacteraemic pneumococcal pneumonia had a mortality of 57%, which was significantly higher than the 25% seen in patients without HIV infection. However, HIV-infected patients without AIDS had a 100% survival rate [35]. In other studies, the mortality rate for bacteraemic pneumococcal pneumonia in patients with HIV infection has been relatively low, ranging from 5–11% [36, 37]; thus, it seems that the prognosis of bacteraemic pneumococcal pneumonia depends on the stage of HIV infection.

Despite the good response to treatment, recurrent episodes of bacterial pneumonia are common in these patients. In one study, 10 out of 17 patients with bacterial pneumonia had a recurrent episode [38]. Seventeen of 31 of our patients had another bacterial pneumonia within a mean of 5 months after recovery. It has also been noted that recurrent bacterial pneumonias may be associated with advanced HIV disease, suggesting a worse prognosis [36]. Undoubtedly, studies on preventive strategies should be performed in order to reduce this high rate of recurrence.

References


